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Background: Pasteurella multocida causes numerous economically relevant diseases in livestock including rabbits.
Immunisation is only variably effective. Prophylactic antibiotics are used in some species but are contra-indicated in
rabbits, due to their adverse effects on the rabbit microbiota. There is therefore a substantial need for alternative
forms of infection control in rabbits; we investigated the effect of oral β-glucan on P. multocida infection in this
species.
Results: Thirthy-five New Zealand White rabbits were randomly divided into five groups of seven animals. Three
groups were inoculated with Pasteurella multocida intranasally (in.), a physiologically appropriate challenge which
reproduces naturally acquired infection, and received either (1–3), (1–6) β-glucans or placebo. Four other groups
were inoculated both in. and intramuscularly (im.), representing a supra-physiological challenge, and received either
(1–3), (1–6) β-glucans, antibiotic or placebo. β-glucans given prophylactically were highly effective in protecting
against physiological (in.) bacterial challenge. They were less effective in protecting against supra-physiological
bacterial challenge (in. and im.), although they extended survival times. This latter finding has practical relevance
to breeders as it extends the window in which heavily infected and symptomatic animals can be salvaged with
antibiotics.
Conclusions: In our study, (1–3), (1–6) β-glucans were highly effective in protecting against a model of naturally
acquired P. multocida infection and extended survival times in the supra-physiological model. Enrofloxacin was
effective in protecting against supra-physiological infection. We are currently reviewing the use of combined
prophylaxis.
Keywords: Pasteurella multocida, β-glucan, RabbitBackground
In infection control, rabbits are important target animals.
They are domestic pets, livestock animals in increasing
demand for meat and fur production, and a widely used
experimental species for human drug research.
Since the European Union (EU) and Regulation (EC)
1831/2003 banned the use of antibiotics as feed additives
in 2006, concerted efforts have been made to find alterna-
tive prophylactics. To date none of the investigated sup-
plements has shown adequate effectiveness, leading to* Correspondence: palocz.orsolya@aotk.szie.hu
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unless otherwise stated.reduced feed conversion rates and increased per-head
veterinary and other costs [1].
In rabbit production, antibiotics are still commonly used
under veterinary prescription during the growth period
(weaning – 56/60 days) to prevent post-weaning enteric
disorders. However, regulatory changes affecting rabbit
production similar to those applied to poultry are ex-
pected shortly [2]. As much rabbit production is small
to medium scale, many producers will be unable to afford
to make substantial changes in husbandry practice. Alter-
native prophylactics are therefore urgently needed.
Pasteurella multocida, a virulent and readily transmitted
coccobacillus, is one of the most significant bacterial dis-
eases of rabbits and causes considerable economic losses
in large production units world-wide [3,4]. Clinical signsLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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pneumonia, otitis media, pyometra, orchitis, abscesses,
oculoconjunctivitis, and septicaemia [5,6]; although infec-
tion may also be asymptomatic [7]. Of the 5 serogroups,
serogroup A and to a lesser extent serogroup D strains are
considered to be causative agents of pasteurellosis in rab-
bits [8]. Rabbits can become infected with P. multocida
immediately after birth, and the prevalence of colonization
increases with age until about 5 months. Most adult rab-
bits are believed to be infected with P. multocida.
Endemic infection, therefore, remains a source of consid-
erable potential loss. Control measures such as enhanced
husbandry and the culling of symptomatic animals reduce
overall morbidity and mortality, but impose signifi-
cant costs. Vaccines targetting P. multocida reduce in-
fection but do not give complete protection under
field conditions [9]. Antibiotics are due to be phased
out, due to such concerns as antibiotic traces in ani-
mal products impacting on human health [10]. In any
case, and despite initial reports of multiple antibiotic
sensitivity, [11,12], the spread of resistance [13] and
the hypersensitivity of rabbits to many antibacterial
agents precludes the aggressive use of antibiotics in
this species [14].
Alternative to antibiotics include probiotics, prebiotics
and a number of phytonutrients, none of which is very
effective. To this list we must now add the β-glucans,
cell wall constituents of bacteria, fungi and plants. The
(1–3), (1–6) fungal β-glucans in particular are recognized
by mammalian cells as pathogen-associated molecular
patterns and thus act as biological response modifiers.
This recognition plays an important role in host defense
and presents specific opportunities for clinical modulation
of the host innate immune response. Experimental and
clinical results show that the (1–3), (1–6) β-glucans act as
broad-spectrum enhancers of host defense mechanisms,
positively influencing the immunological response of mam-
mals including humans to bacterial, viral, and fungal infec-
tions [15].
The aim of this present study was to observe and
describe the effect of a (1–3), (1–6) β-glucan dietary
supplement on physiological and a supra-physiological
P. multocida infection in rabbits.Table 1 Experimental schedule
Group name Days 8–14 at 8 am
Control 0.5% methylcellulose 1 ml/kg
Positive control 0.5% methylcellulose 1 ml/kg
Antibiotic 0.5% methylcellulose 1 ml/kg
Small dose beta-glucan 5 mg/kg beta-glucan in 0.5% methy
High dose beta-glucan 50 mg/kg beta-glucan in 0.5% meth
The substances were administered to the rabbits in the concentrations above, accoMethods
Bacterial isolates and growth conditions
Pasteurella isolates were stored in a solution of 30% glycerol
at −80°C. Isolates were grown in tryptic soy broth at 36°C.
For the isolation of P. multocida from clinical samples,
swabs were streaked onto blood agar plates and incu-
bated at 36°C for 24 hours.
Rabbits, housing and treatments
Thirty-five, clinically healthy, seven week old, 20 female
and 15 male New Zealand White rabbits (S & K Lap
Nyúltenyésztő Kft., Kartal, Hungary) were used in this
study. The animals were housed in stainless steel cages
(40×60×80 cm), two rabbits per cage in the animal
housing facility of the Department of Pharmacology and
Toxicology, acclimated at 20 ± 2°C on a 12 h light 12 h
dark schedule. One hundred grams of commercial pellet
feed was provided daily, water was available ad libitum.
A microchip was implanted sub-dermally (cervical region)
in each animal for validated identification. The rabbits
(mean weight 1105 ± 87 g) were randomly divided into
5 groups (7 rabbits/group) comprising 1 control group
and 4 experimental groups: positive controls, antibiotic-
treated, low dose β-glucan (5 mg/kg bw.) and high dose
β-glucan (50 mg/kg bw.) (Table 1).
The experimental schedule included acclimatization
for 7 days, pre-treatment for 14 days, inoculation, and
subsequent post-treatment for 7 days. During the pre-
treatment phase from day 8 to 21, β-glucan was delivered
in aqueous solution via probe, made up with 0.5% w/v
methylcellulose. Animals in the control and antibiotic
groups received pure methylcellulose solution. After chal-
lenge with P. multocida (see below), in the control groups
the daily single administration of placebo was continued.
On the day of challenge and thereafter, animals in the
antibiotic group daily received enrofloxacin 10 mg/kg bw.,
diluted ten times in 0.5% methylcellulose.
Bakers yeast β-glucan (Immivet® 3–6 Dispersible Powder)
was supplied by Biothera Company (Eagan, MN 55121,
USA).
Methylcellulosum USP; Molar Chemicals Ltd, Budapest,
Hungary.Days 15–21 at 8 am
0.5% methylcellulose 1 ml/kg
0.5% methylcellulose 1 ml/kg
1% enrofloxacin in 0.5% methylcellulose
lcellulose 5 mg/kg beta-glucan in 0.5% methylcellulose
ylcellulose 50 mg/kg beta-glucan in 0.5% methylcellulose
rding to the time schedule.
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Ltd., Szekszárd, Hungary.Bacterial challenge and subsequent monitoring
Bacterial challenges were administered on Day 15. In the
three physiological model groups, animals were given
in. 0.5 ml physiological saline containing approximately
108 CFU of a cocktail of ten lapine isolates of P. multo-
cida. In the four supra-physiological model groups, an-
imals received 0.5 ml of the same bacterial suspension
both in. and im. Rectal temperature and clinical status
of all rabbits were monitored twice daily. The clinical
signs were scored as follows: breathing sound 0 – normal,
1 – respiratory murmur; nasal discharge 0 – absent, 1 –
present; conjunctivitis 0 – absent, 1 – present; attitude 0 –
active, 1 – depressed; appetite 0 – normal, 1 – decreased.
A total clinical score was calculated for each individual
rabbit (0–5). Challenged rabbits in the terminal stage of
the disease and those which survived until 7 days pi. were
euthanized by sodium pentobarbital overdose (100 mg/kg
bw. ip., Euthasol® 40% injection, Produlab Pharma B.V.,
Netherlands).Pathology
All challenged and control rabbits were examined for
gross and histological lesions. Lungs, liver, spleen, kid-
neys and nasal mucosa were histologically examined in
all rabbits. The samples were fixed in 8% neutral buffered
formalin for 24 h and embedded in paraffin wax. Sections
(3–4 μm) were cut, stained with hematoxylin and eosin,
and examined by light microscopy.Table 2 Primer sequences for identification and detection of
Gene Primer sequence
kmt1 F - ATCCGCTATTTACCCAGTGG
R - GCTGTAAACGAACTCGCCAC
hyaC-hyaD F - TGCCAAAATCGCAGTCAG
R - TTGCCATCATTGTCAGTG
pfhA F - AGCTGATCAAGTGGTGAAC
R - TGGTACATTGGTGAATGCTG
nanH F - GAATATTTGGGCGGCAACA
R - TTCTCGCCCTGTCATCACT
hgbA F - TGGCGGATAGTCATCAAG
R - CCAAAGAACCACTACCCA
ompH F - CGCGTATGAAGGTTTAGGT
R - TTTAGATTGTGCGTAGTCAAC
ptfA F - TCCACTCGTTGTGGCATTCA
R - AGAAACACCTTGAGCTGCGTPCR analyses and gel electrophoresis
Total DNA of bacterial strains was isolated with E.Z.N.
A. bacterial DNS kit (OMEGA Bio-Tek, Norcross, USA)
according to the manufacturer’s recommendations.
The identity of isolates was confirmed by PCR. PCR
was performed using 5PRIME HotMasterMix (5PRIME
GmbH, Hamburg, Germany) on the MiniOpticon System
(BioRad). For each PCR reaction, 2.5 μl DNA was added
directly to a PCR reaction mixture, set to a final volume of
25 μl, containing × 1 concentrated HotMasterMix and
0.2 μM of the appropriate primers. The DNA-sequences of
oligonucleotide primers are listed in Table 2. The thermal
profile for all reactions was 2 min at 95°C, then 30 cycles
of 30 s at 95°C, 30 s at 60°C and 30 s at 72°C. The PCR
was terminated with a final extension at 72°C for 5 min.
The PCR amplicons were separated by electrophoresis
in 2% agarose gel, the resulting bands were visualised
and scanned by the InGenius LHR Gel Documentation
and Analysis System (Syngene).
Statistical analyses
Statistical analyses were performed by Statistica 12 soft-
ware (Statsoft, Tulsa, USA). Differences between means
were evaluated by one-way analysis of variance (ANOVA)
followed by a post hoc comparison using Fisher’s least sig-
nificant difference (LSD) test. Survival curves were calcu-
lated using the Kaplan-Meier method, the curves were
compared using the Cox’s F test. Statistical significance
was set at p <0.05.
Ethical approval
The experiment was conducted according to approved
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Figure 1 Mean rectal temperature of rabbits before and after physiological (in.) P. multocida challenge. Day 0 indicates the day of the
challenge. Significant differences between groups are indicated with asterisk (*p <0.05). Data are shown as means + SEM.
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conditions set up by the code of practice for the care
and use of animals for experimental purpose. The study
was authorised by the Local Institutional Animal Care
Committee (Munkahelyi Állatjóléti Bizottság, MÁB)
(no. 51/2013).
Results
In the physiological model, at 24 hours after physiological
challenge (in. only), infected animals developed conjunctiv-
itis and significantly increased rectal temperature (p ≤0.05),
clinical score ranged between 1 and 2. Animals exposed to
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Figure 2 Mean rectal temperature of rabbits before and after severe
the challenge. Significant differences between groups are indicated with asto the above, nasal discharge and respiratory murmur,
clinical score ranged between 3 and 5. Rectal temperature
significantly increased 24 hours after both challenges
(p ≤0.05) and (p ≤0.01) (Figures 1 and 2). The control
rabbits showed no clinical signs.
In the animals exposed to physiological (in.) challenge,
autopsy findings were relatively minor (see Additional
file 1); nasal mucosa showed epithelial damage and in-
flammatory infiltration and the lungs were affected by
interstitial pneumonia (Figure 3A-B), but macroscopic
lesions did not develop. Tissues collected from the con-
trol and β-glucan treated groups were healthy and intact







ay 2 morning day 2 afternoon
(in. and im.) P. multocida challenge. Day −1 indicates the day before
terisks (*p <0.05; **p <0.01). Data are shown as means + SEM.
Figure 3 Representative photomicrographs of (a, c) lung tissue
and (b, d) nasal mucosa from rabbits infected intranasally with
P. multocida. (a) Lung from the positive control (untreated) animals
showing interstitial inflammatory reaction, and (c) normal lung from
the β-glucan treated animals. (b) Nasal mucosa from the positive
control (untreated) animals showing epithelial necrosis and intensive
heterophil granulocyte infiltration with submucosal edema. (d) Normal
nasal mucosa from the β-glucan treated animals. Hematoxylin and
eosin stain; magnification, 100×.
Palócz et al. BMC Veterinary Research 2014, 10:276 Page 5 of 7
http://www.biomedcentral.com/1746-6148/10/276challenged rabbits nasal cavities. In the supra-physiological
model (rabbits infected in. and im.), autopsy revealed con-
gested heart accompanied with enlarged and congested
blood vessels, necrotic foci in the liver, brown peritoneum,
congested friable kidneys, and dark brown spleen. Trachea,
lungs, and heart were congested, hyperemic and filled with
blood. The lungs showed peribronchitis, severely con-
gested vessels with vasculitis, marked alveolar collapse,
diffused interstitial inflammatory reaction and intra-
alveolar tissue destruction. Positive control and β-glucan
animals showed similar pathology. The enrofloxacin treated
group had milder symptoms; interstitial pneumonia and
Pasteurella septicaemia occurred but necrotic lesions and
macroscopical signs were not seen. P. multocida were cul-
tured back from all inflammatory foci.
β-glucan treatment did not reduce the numbers of
deaths in the supra-physiological model but did post-
pone death by several days. Either low-dose or high-dose
β-glucan treatment marginally delayed death but the delay
was statistically significant when both β-glucan treatments
were compared to the positive control group together
(Figure 4). In field conditions, this extended window of
opportunity for antibiotic intervention would have consid-
erable implications for veterinary management.
All ten P. multocida isolates administered to the rab-
bits were shown to be sensitive to enrofloxacin in the
disk diffusion test. The inhibition zone diameters were
between 21–25 mm. All ten P. multocida isolates har-
boured the species-specific gene sequence (kmt), porin
protein encoding gene (ompH), hemoglobin binding pro-
tein encoding gene (hgbA), filamentous hemagglutinin
encoding gene (pfhA), neuraminidase gene (nanH) and 8
of 10 isolates were contained the type 4 fimbriae gene
(ptfA). 8 of ten isolates were positive for capA capsule
biosynthesis gene.Discussion
In rabbit husbandry, good environmental control is critical
in reducing the burden of infection. Common symptoms
including nasal discharge, sneezing and conjunctivitis are
most frequently due to Pasteurella multocida, which is
also the major cause of morbidity and mortality. P. multo-
cida may also cause abscesses in subcutaneous and other
Figure 4 Impact of β-glucan treatements on rabbits infected
intranasally and intramuscularly with P. multocida. Rabbits were
received methylcellulose solution (positive controls, n = 7) and either
low-dose (n = 7) or high-dose (n = 7) β-glucan (5 or 50 mg/kg bw.).
Curves were calculated by Kaplan-Meier method and Cox’s F test
was used for comparisons between treatments. Positive control x
low-dose β-glucan (F = 2.306, p = 0.065), positive control x high-dose
β-glucan (F = 2.344, p = 0.065), positive control x both β-glucan
treatments (F = 2.408, p = 0.044).
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and septicaemia [13].
Fluoroquinolones such as enrofloxacin are concentration-
dependent bactericides with activity against many pathogens
including P. multocida. Tissue levels two to three times
higher than that found in the serum have been demon-
strated in various species, and the fluoroquinolones are
relatively safe in rabbits [16], but questions regarding ef-
fectiveness remain. For example, enrofloxacin (5 mg/kg
bw.) given orally to rabbit does stopped transmission of
Pasteurella to their young but failed to eliminate infection
from the mother rabbits themselves [17]. Enrofloxacin
given at 5 mg/kg im. eliminated P. multocida from nearly
all adult rabbits but in rabbits given enroflaxacin orally, al-
though the nasal flush cultures were negative, the nec-
ropsy cultures from nasopharynx, cavity, tympanic cavity,
and lung were all positive [17]. These findings correspond
with our results, where animals treated with 10 mg/kg
enrofloxacin p.o. showed less serious clinical signs and
necropsy alterations, but interstitial pneumonia still
occured.
It is generally acknowledged that Pasteurellosis in rab-
bits should be managed rather than treated, but the failure
of oral enrofloxacin to eradicate P. multocida and the sub-
sequent risk of resistance has led to regulatory pressure to
phase these drugs out and seek alternatives. The (1–3),
(1–6) β-glucans are prime candidates. Numerous studies
have shown that these natural compounds exhibitanti-infective and anti-tumour properties, mediated by
immuno-priming. In immuno-priming, β-glucans bind to
the CR-3 receptor present on innate immune cells result-
ing in enhanced chemotaxis, phagocytosis and microbial
killing [18]. This has been shown to confer protection
against many pathogens including anthrax, a lethal disease
that affects animals and humans. In one study conducted
in association with the Canadian Department of Defence
[19], orally administered Immivet® 3–6 (2 and 20 mg/kg
body weight) given for eight days prior to innoculation
with Bacillus anthracis provided almost complete protec-
tion against infection over the 10-day post-exposure test
period.
The result of our study indicates that clinical disease
caused by physiological exposure to P. multocida can be
prevented with oral β-glucans. This protective action
should enable reduced antibiotic use in livestock and
pets, leading to improved food safety and reduced spread
of resistance. The immuno-priming activity of the (1–3),
(1–6) β-glucans when given together with antibiotics has
been shown to increase the effectiveness of the antibi-
otics [20]. This will be evaluated in further trials.Conclusions
Supra-physiological exposure to P. multocida (in. and im.
innoculation) is lethal in rabbits. Physiological exposure
(in. only) creates a milder and non-lethal infection. We
used Pasteurella isolates with serious virulence-associated
genes (ompH, hgbA, pfhA, nanH, ptfA). After supra-
physiological exposure, only the enrofloxacin treatment
was clinically effective, and even the antibiotic treated
group suffered from septicaemia. β-glucan treatment did
not prevent death, although it delayed death considerably
compared to controls. β-glucan was, however, highly
effective in protecting against physiological exposure
to P. multocida, preventing any histological damage. Our
results suggest that β-glucan feeding should be preventive
against clinical Pasteurellosis in rabbits.Additional file
Additional file 1: Evaluation of the histological sections of
lungs, spleen, liver, kidneys, and nasal mucosa derived from
the intranasally challenged (P. multocida) rabbits. The +/−
indicates the presence/absence of histopathological alterations,
respectively.Abbreviations
bw.: bodyweight; CFU: colony forming unit; CR-3: complement receptor 3;
im.: intramuscular; in.: intranasal; ip.: intraperitoneal; MÁB: Munkahelyi
Állatjóléti Bizottság (Local Institutional Animal Care Committee);
pi.: postinfection; P.: Pasteurella; p.o.: per os; SEM: standard error of mean.
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